The NIEHS is interested in developing, standardizing, and validating sensitive and specific new and novel tests or batteries of tests that will provide faster and less expensive alternatives to the use of standard laboratory animal tests,( i.e., assays for carcinogenicity, immunotoxicity, reproductive or developmental toxicity, dermal toxicity, and neuro or other organ system toxicity including acute local and systemic toxicity). The proposed tests should use cell cultures or animal models that are relevant to human experience and can be extrapolated to estimate risk to humans. The NIEHS is interested in developing both high throughput screens that can be used to prioritize chemicals for definitive testing and in developing specific tests that meet regulatory requirements for toxicity tests. The endpoints for these assays should take advantage of the new technologies such as genomics, transcriptomics, proteomics, and bioinformatics and of novel endpoints (biomarkers) including those that are non-invasive. Examples include but are not limited to:
The NIEHS contact person is: Jerrold J. Heindel, Ph.D. |
|